HCPCS Level II code Q5124 identifies the biosimilar ranibizumab-nuna (Byooviz) in a 0.1 mg presentation for intravitreal injection. This code is significant nationally as biosimilar anti-VEGF agents expand therapeutic options for retinal diseases, with implications for utilization, payer coverage policies, and cost management across outpatient ophthalmology settings. Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

Readers will find a concise overview of what Q5124 represents clinically and operationally, plus benchmarking context and policy-relevant considerations: typical sites of service for administration, common billing practices, expected reporting details, and where to look for payer coverage nuances. The publication outlines benchmarks for utilization and reimbursement approaches, summarizes recent policy updates affecting biosimilar ophthalmic injectables, and provides clinical context around intravitreal anti-VEGF therapy. Data not included in the input are noted where applicable. This piece is intended to inform revenue cycle managers, coding professionals, and policy analysts about the role and coding of ranibizumab-nuna in outpatient retinal care.